@article {Hosier2020.04.30.20083907, author = {Hillary Hosier and Shelli Farhadian and Raffaella A. Morotti and Uma Deshmukh and Alice Lu-Culligan and Katherine H. Campbell and Yuki Yasumoto and Chantal B.F. Vogels and Arnau Casanovas-Massana and Pavithra Vijayakumar and Bertie Geng and Camila D. Odio and John Fournier and Anderson F. Brito and Joseph R. Fauver and Feimei Liu and Tara Alpert and Reshef Tal and Klara Szigeti-Buck and Sudhir Perincheri and Christopher Larsen and Aileen M. Gariepy and Gabriela Aguilar and Kristen L. Fardelmann and Malini Harigopal and Hugh S. Taylor and Christian M. Pettker and Anne L. Wyllie and Charles Dela Cruz and Aaron M. Ring and Nathan D. Grubaugh and Albert I. Ko and Tamas L. Horvath and Akiko Iwasaki and Uma M. Reddy and Heather S. Lipkind}, title = {SARS-CoV-2 infection of the placenta}, elocation-id = {2020.04.30.20083907}, year = {2020}, doi = {10.1101/2020.04.30.20083907}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The effects of Covid-19 in pregnancy remain relatively unknown. We present a case of second trimester pregnancy with symptomatic Covid-19 complicated by severe preeclampsia and placental abruption.Methods We analyzed placenta for the presence of SARS-CoV-2 through molecular and immunohistochemical assays and by and electron microscopy, and we measured the maternal antibody response in blood to this infection.Results SARS-CoV-2 localized predominantly to syncytiotrophoblast cells at the maternal-fetal interface of the placenta. Histological examination of the placenta revealed a dense macrophage infiltrate, but no evidence for vasculopathy typically associated with preeclampsia.Conclusion This case demonstrates, for the first time, SARS-CoV-2 invasion of the placenta, highlighting the potential for severe morbidity among pregnant women with Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata links in manuscript (sequencing)}, URL = {https://www.medrxiv.org/content/early/2020/05/07/2020.04.30.20083907}, eprint = {https://www.medrxiv.org/content/early/2020/05/07/2020.04.30.20083907.full.pdf}, journal = {medRxiv} }